From: Prognostic analysis of 2–5 cm diameter gastric stromal tumors with exogenous or endogenous growth
Characteristics | Exogenous (n = 375) | Endogenous (n = 121) | p-value |
---|---|---|---|
Age (%) | 0.023 | ||
≤ 65 | 270 (76.1) | 75 (61.9) | |
> 65 | 105 (23.9) | 46 (38.1) | |
Gender (%) | 0.987 | ||
Female | 210 (43.5) | 67 (55.4) | |
Male | 165 (56.5) | 54 (44.6) | |
Rupture (%) | 0.001 | ||
No | 370 (94.1) | 120 (99.2) | |
Yes | 5 (5.9) | 1 (0.8) | |
Tumor site (%) | 0.013 | ||
Small bend | 130 (34.7) | 38 (31.4) | |
Large bend | 156 (41.6) | 60 (49.6) | |
Fundus | 89 (23.7) | 23 (19.0) | |
Tumor size (%) | 0.002 | ||
< 5 cm | 37 (9.8) | 11 (9.1) | |
2–5 cm | 192 (51.2) | 83 (68.6) | |
> 5 cm | 146 (39.0) | 27 (22.3) | |
Mitotic index (%) | 0.403 | ||
≤ 5/HPF | 268 (71.5) | 92 (76.0) | |
> 5/HPF | 107 (28.5) | 29 (24.0) | |
NIH risk grade (%) | 0.057 | ||
Extremely low or low | 189 (50.4) | 76 (62.8) | |
Moderate or high | 186 (49.6) | 45 (37.2) | |
CD117 (%) | 0.775 | ||
( −) or ( +) | 103 (27.5) | 29 (24.0) | |
(+ +) or (+ + +) | 272 (72.5) | 95 (76.0) | |
CD34 (%) | 0.696 | ||
( −) or ( +) | 69 (18.4) | 12 (10.0) | |
(+ +) or (+ + +) | 306 (81.6) | 109 (90.0) | |
Surgical history (%) | 308 (82.1) | 95 (78.5) | 0.451 |
HB (X̄) | 127 | 124 | 0.124 |
ALB (X̄) | 40.4 | 39.95 | 0.172 |
Adjuvant imatinib (%) | 279 (74.4) | 87 (72.0) | 0.671 |
Basic disease (%) | 215 (57.3) | 68 (56.2) | 0.909 |
Resection style (%) | 0.026 | ||
Mesenchymal resection | 331 (88.3) | 96 (79.3) | |
Distal gastrectomy | 14 (3.7) | 12 (10.0) | |
Proximal gastrectomy | 18 (4.8) | 10 (8.3) | |
Total gastrectomy | 12 (3.2) | 3 (2.4) | |
Surgery time (min) | 120 | 115 | 0.884 |
Intraoperative bleeding(ml) | 50 | 50 | 0.030 |